Saturday 17 October 2026
Export SVRA’s income statement to Excel — free account
Savara Inc.
SVRA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 14.3%, free cash flow fell 14.1% and total debt rose 1.54%, each against the same quarter a year earlier.
4.45
0.29
−6.12%
Follow SVRA
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — | 0.00 | — | — | — | — | — |
Altman Z-Score |
— | — | — | — | (3.18) | — | — | — | — | — |
P/S ratio |
0.00 | — | — | — | 0.00 | — | — | — | — | — |
P/FCF ratio |
510.27 | — | — | — | 0.00 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(3.94) | — | — | — | (4.79) | — | — | — | — | — |
P/Operating CF |
(9.33) | — | — | — | (5.55) | — | — | — | — | — |
P/B ratio |
6.10 | — | — | — | 1.06 | — | — | — | — | — |
Price to Tangible BV |
19.76 | — | — | — | 1.52 | — | — | — | — | — |
EV/Sales |
0.00 | — | — | — | 0.00 | — | — | — | — | — |
EV/EBITDA |
0.00 | — | — | — | 0.00 | — | — | — | — | — |
EV/Operating CF |
195.53 | — | — | — | (0.28) | — | — | — | — | — |
EV/FCF |
428.65 | — | — | — | (0.28) | — | — | — | — | — |
Quick Ratio |
3.99 | 15.68 | 15.28 | 11.19 | 10.05 | 10.99 | 21.45 | 15.32 | 13.33 | 11.56 |
Current Ratio |
4.23 | 16.27 | 15.63 | 11.40 | 10.41 | 11.26 | 21.98 | 15.66 | 13.73 | 11.85 |
Net Debt/EBITDA |
0.86 | 2.69 | 1.23 | 1.87 | 1.18 | 3.48 | 2.61 | 2.11 | 1.57 | 1.64 |
Debt/Assets |
15.45% | 9.61% | 16.13% | 18.44% | 25.87% | 14.53% | 18.66% | 14.84% | 12.50% | 11.80% |
Debt/Equity |
0.56 | 0.13 | 0.23 | 0.25 | 0.39 | 0.18 | 0.24 | 0.19 | 0.16 | 0.15 |
Asset Turnover |
0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.76 | 0.92 | 0.64 | 0.58 | 0.80 | 0.93 | 0.91 | 0.93 | 0.93 | 0.85 |
Capex/Depreciation |
(0.01) | (0.79) | (1.50) | (0.01) | (0.04) | (0.02) | (0.02) | 0.07 | 0.01 | 0.01 |
Interest Coverage |
(24.22) | (25.80) | 6,367.73 | (1,128.93) | (33.27) | (18.18) | (441.35) | — | — | — |
| 183.83% | (73.78%) | (54.07%) | (74.48%) | (59.75%) | (41.19%) | (30.24%) | (44.08%) | (61.50%) | (63.45%) | |
| (26.50%) | (32.65%) | (39.44%) | (54.19%) | (42.42%) | (31.36%) | (24.12%) | (34.47%) | (49.11%) | (50.97%) | |
ROIC |
0.00% | (46.42%) | (199.35%) | (978.23%) | (412.04%) | (288.58%) | (304.19%) | (852.18%) | (3,704.62%) | 0.00% |
Return on Tangible Assets |
(92.18%) | (33.18%) | (57.70%) | (68.85%) | (64.35%) | (28.60%) | (30.98%) | (35.15%) | (51.12%) | (53.69%) |
Average Days of Receivables |
365.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
2,045.50% | 0.00% | 0.00% | 0.00% | 13,633.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
705.00% | 0.00% | 0.00% | 0.00% | 5,550.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.11 | 0.17 | 0.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
52.25% | 0.00% | 0.00% | 0.00% | 1,987.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.05) | — | — | — | 0.76 | — | — | — | — | — |
Graham Number |
60.03 | — | — | — | 0.00 | — | — | — | — | — |
Earnings Yield |
(70.38%) | — | — | — | (72.58%) | — | — | — | — | — |
Free Cash Flow Yield |
0.20% | — | — | — | (58.47%) | — | — | — | — | — |
Revenue per Share |
0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(4.27) | (1.61) | (1.18) | (1.13) | (0.67) | (0.30) | (0.23) | (0.31) | (0.45) | (0.45) |
Capex per Share |
0.00 | (0.03) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(4.27) | (1.64) | (1.18) | (1.13) | (0.67) | (0.30) | (0.23) | (0.31) | (0.45) | (0.45) |
Cash per Share |
6.82 | 5.38 | 3.33 | 3.04 | 1.39 | 1.20 | 0.82 | 0.98 | 0.99 | 1.06 |
Shareholders Equity per Share |
4.07 | 6.81 | 3.25 | 2.54 | 1.09 | 1.08 | 0.71 | 0.85 | 0.87 | 0.91 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.07 | 6.81 | 3.25 | 2.54 | 1.09 | 1.08 | 0.71 | 0.85 | 0.87 | 0.91 |
Free Cash Flow |
(8.38) | (28.73) | (39.42) | (45.27) | (39.88) | (40.14) | (34.56) | (51.36) | (89.11) | (101.06) |
Working Capital |
11.16 | 91.85 | 106.09 | 113.19 | 76.95 | 150.34 | 123.09 | 155.35 | 187.41 | 221.22 |
Capital Expenditures |
(0.01) | (0.49) | (0.14) | (0.15) | (0.05) | (0.06) | (0.01) | (0.30) | (0.02) | (0.02) |
Net Current Asset Value |
(6.33) | 57.55 | 69.28 | 89.56 | 51.76 | 132.90 | 96.96 | 128.76 | 160.71 | 191.31 |
EV/EBIT |
0.00 | — | — | — | 0.00 | — | — | — | — | — |
Capex to Sales |
0.02 | 0.00 | 0.00 | 0.00 | 0.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | — | — | — | 0.00 | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.78 | 0.68 | 0.18 | 77.51 | 8.04 | 34.56 | 11.29 | (16.81) | (29.67) | (21.68) |
Cash ROIC |
(32.44%) | (12.55%) | (16.18%) | (18.21%) | (23.21%) | (12.11%) | (13.31%) | (15.61%) | (22.59%) | (21.56%) |
Accounts Receivable Turnover |
1.92 | 0.00 | 0.00 | 0.00 | 0.16 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.21 | 0.72 | 1.36 | 1.65 | 1.66 | 1.42 | 1.05 | — | — | — |
Average Payables |
1.57 | 1.66 | 3.33 | 3.64 | 3.00 | 2.02 | 1.39 | 2.42 | 4.02 | 5.15 |
Average Assets |
41.58 | 94.28 | 155.96 | 144.25 | 116.97 | 137.17 | 158.19 | 158.67 | 195.22 | 233.16 |
Average Common Equity |
(5.99) | 41.72 | 113.76 | 104.96 | 83.04 | 104.44 | 126.14 | 124.08 | 155.91 | 187.29 |
Columns are period end dates